Opportunity, it is a bit early to get all fired up about a patent application. You will need to see what the patent examiner has to say.
As far as comparing RECAF to DR70 and HaaH, for diagnostics, they are all in the same category and will not have much if any impact at all.
As far as the patent application, that is the first thing in a long time that has even tweeked my interest in RECAF. I have always stated that RECAF could be used for therapeutics just like Constab has proven. Moro's problem was NO PATENT.
Now, also consider that Panacea also has an issued patent for using the HaaH maker to deliver therapeutics. If they come up with a good delivery antibody, what possibilites does that open up. From what I have read, I think the Haah marker is slightly better for diagnosics than RECAF.
Even if Moro's patent does get approved, I still have no interest in owning any of this stock. The company is just horribly run and the trust factor is zero.